Paula Byrne, PhD; Maryanne Demasi, PhD; Mark Jones, PhD; et al.
free access
JAMA Intern Med. 2022;182(5):474-481. doi:10.1001/jamainternmed.2022.0134
This systematic review and meta-analysis examines the association between absolute reductions in low-density lipoprotein cholesterol levels with treatment with statin therapy and all-cause mortality, myocardial infarction, and stroke.
Less Is More
Ushma D. Upadhyay, PhD, MPH; Elizabeth G. Raymond, MD, MPH; Leah R. Koenig, MSPH; et al.
open access
JAMA Intern Med. 2022;182(5):482-491. doi:10.1001/jamainternmed.2022.0217
This cohort study evaluates the outcomes and safety of a history-based screening, no-test approach to medication abortion care.
Benjamin Eckhardt, MD; Pedro Mateu-Gelabert, PhD; Yesenia Aponte-Melendez, PhD; et al.
free access
JAMA Intern Med. 2022;182(5):494-502. doi:10.1001/jamainternmed.2022.0170
This randomized clinical trial examines the efficacy of an accessible care model for treating hepatitis C virus in people who inject drugs.
-
Editor's Note
Curing Hepatitis C—Requires More Than a Prescription
Asha Choudhury, MD, MPH, MS; Mitchell H. Katz, MD
JAMA Intern Med
Assiamira Ferrara, MD, PhD; Monique M. Hedderson, PhD; Yeyi Zhu, PhD; et al.
free access
JAMA Intern Med. 2022;182(5):503-512. doi:10.1001/jamainternmed.2022.0330
This cohort study examines the risk for perinatal complications in pregnant individuals with SARS-CoV-2 infection.
Liyun He, MM; Jialu Wang, MM; Fan Ping, MD; et al.
free access
JAMA Intern Med. 2022;182(5):513-519. doi:10.1001/jamainternmed.2022.0338
This systematic review and meta-analysis of 76 randomized clinical trials examines the effects of glucagon-like peptide-1 receptor agonist use on the risk of gallbladder and biliary diseases.
Loreen Straub, MD, MS; Sonia Hernández-Díaz, MD, DrPH; Brian T. Bateman, MD, MS; et al.
free access
JAMA Intern Med. 2022;182(5):522-533. doi:10.1001/jamainternmed.2022.0375
This nationwide birth cohort study of 3.4 million children nested in nationwide health care utilization data with up to 14 years of follow-up evaluates the risk of specific neurodevelopment disorders associated with in utero exposure to antipsychotic medications.
Elizabeth A. Bayliss, MD, MSPH; Susan M. Shetterly, MS; Melanie L. Drace, MPH; et al.
open access
JAMA Intern Med. 2022;182(5):534-542. doi:10.1001/jamainternmed.2022.0502
This cluster randomized clinical trial examines the effectiveness of educating patients and clinicians about the potential to deprescribe unnecessary or risky medications among patients with dementia or mild cognitive impairment.